6ER-011 Drug utilisation study of bevacizumab in a teaching referral paediatric hospital

BACKGROUND: Bevacizumab is a humanised monoclonal antibody against vascular endothelial growth factor authorised for adult cancer treatments. There are several case series and clinical trials on the use of bevacizumab in paediatric tumours at dose range of 5 to 15 mg/kg every 2 to 4 weeks. PURPOSE:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Hosp Pharm
Main Authors: Celma, M Sánchez, Busquets, F Bossacoma, Genestar, JL Vinent, Suárez, J Arrojo, Flaqué, M Villaronga, Escoda, A Comes, López, V Santa-María, Alcón, P Montoliu
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2018
Assuntos:
Section 6: Education and research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535719/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.504
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados